CollPlant operates as a company focused on regenerative and cosmetic medicine, with a commitment to developing pioneering technologies and products for the regeneration of tissue and the fabrication of organs. Their groundbreaking plant-derived technology stands as the sole commercially feasible method for the large-scale production of synthetic human Type I collagen (rhCollagen), which mirrors the collagen generated by the human body. This makes their rhCollagen the perfect foundational component for regenerative medicine. Capitalizing on the distinctive attributes of rhCollagen and expertise in biomaterials, they are in the process of creating a range of products aimed at 3D printing of tissues and organs, as well as enhancements in medical aesthetics.